ロード中...
γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct
γ‐Secretase inhibitors (GSIs) are being actively repurposed as cancer therapeutics based on the premise that inhibition of NOTCH1 signaling in select cancers is therapeutic. Using novel assays to probe effects of GSIs against a broader panel of substrates, we demonstrate that clinical GSIs are pharm...
保存先:
| 出版年: | EMBO Mol Med |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5494507/ https://ncbi.nlm.nih.gov/pubmed/28539479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201607265 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|